Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06407310 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06407310 · ClinicalTrials.gov record · last posted 2024-05-09

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

Name: Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer — clinical trial record (NCT06407310)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorTel Aviv Medical Center

Started2024-07-01

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a phase II, single-centered, open-label, single-armed study in patients with early triple-negative breast cancer that will evaluate the pathological complete response (pCR) rate of a non-anthracycline-based chemo-immunotherapy regimen. The trial includes a lead-in cycle of pembrolizumab, then a combination of paclitaxel, carboplatin, and pembrolizumab in the neoadjuvant setting.

Trial Details

NCT Number	NCT06407310
Lead Sponsor	Tel Aviv Medical Center
Conditions	Triple Negative Breast Cancer
Enrollment	25 participants
Start Date	2024-07-01
Primary Completion	2027-04-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2024-05-09